Spanish pharmaceutical companies recover and grow by 12% – Expansión

From left to right and from top to bottom, Gianfranco Nazzi, CEO of Almirall; Mariano Ucar, president of Faes Farma; Vctor Grifols Deu, CEO of Grifols; José María Fernández-Sousa chairs PharmaMar; Ignasi Biosca, CEO of Reig Jofre; and Juan López-Belmonte, president and CEO of Rovi. The progressive normalization of medical consultations and surgeries after the stoppage due to Covid contribute to the national listed companies increasing their income to 4,125 million. The seven pharmaceutical companies that are listed on the Spanish Stock Exchange (Almirall, Faes Farma, Grifols, Oryzon Genomics, PharmaMar , Reig Jofre and Rovi) increased their joint revenues by 12% in the first half of the year, to a total of 4,125 million euros. The be To continue reading go Premium
Try it for €1 the first month and enjoy unlimited access to all the web content of Expansión I want it Or subscribe with your Google account in two clicks